Literature reporting on the ability of dogs to recognize malignant tissue has been published in the past few years. The original report by Williams and Pembroke 9 in 1989 described a patient who became concerned about a cutaneous lesion because her dog was interested in that particular lesion but none of the other lesions on her skin. Excision revealed a malignant melanoma. Subsequent articles reported canine ability to distinguish not only other cutaneous lesions, but also bladder, 10 lung, 11 colon, 12 prostate, 12 and breast 13 cancers. The most recently published reports discuss a dog's ability, with training, to distinguish malignant ovarian tissue from normal nonmalignant ovarian tissue. In one report, a Schnauzer was able to accurately differentiate between malignant and nonmalignant ovarian tissue with 100% sensitivity and 97.5% specificity. 6 The only error occurred when the dog was presented a tissue sample containing malignant metastatic endometrial cancer. A subsequent study compared the dog's olfactory ability to distinguish the blood of patients with ovarian cancer from that of patients without malignancy, noting similar sensitivities and specificities. 7 Subsequent trials again attempted using an electronic nose, which had been designed to detect low concentrations of volatile chemicals. The success rate of the manufactured nose was lower, however, with 84.4% and 86.8% sensitivity and specificity, respectively. 8 Similar findings were reported for electronic noses in a study of breath exhaled from patients with lung cancer compared with control subjects. 14 Researchers hypothesize that that the tumors produce volatile chemicals yet to be identified. The dogs' sensitive olfactory senses are able to detect these compounds more accurately than our best current electronics. 15 The ideas and viewpoints expressed in this editorial are those of the author and do not necessarily represent any policy, position, or program of NCCN. Although they may seem odd, pursuing these biologic approaches does have certain advantages. First, this type of tumor detection involves no radiation exposure, which eliminates one concern of many for those who are concerned with radiation risks associated with large-scale population cancer screening. This low-tech approach is also associated with substantially lower costs. Patient confidentiality also ceases to be a concern (aside from the human technicians), because dogs cannot disclose protected health information.
Despite the unusual nature of this screening, now may be the time for us to try to overcome the inherent difficulties in designing prospective clinical trials using animals, including training enough of them. Experience has proven that dogs can be trained in sufficient numbers to be used for detection of illicitly transported drugs. Similarly, dogs are regularly trained to be the eyes and ears of the blind. Perhaps now is the time for a colleague's prediction to come true. Her response to the original manuscript reporting these observations was,"Now instead of a CAT scan, I will have a DOG scan?" Perhaps we might better define this as a "modern PET scan."
